Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer

Integrating CDK4/6 inhibitors in the treatment of patients with early breast cancer

Blog Article

CDK4/6 inhibitors have an established role in the treatment of hormone receptor positive HER2-negative advanced breast cancer.All studies conducted in metastatic breast cancer showed a benefit in delaying progression when added to standard endocrine therapy, regardless of therapy line, pretreatment, menopausal status, site here of metastasis, CDK4/6 inhibitor used and associated endocrine therapy.A benefit in overall survival has also been moondrop quarks demonstrated.In early breast cancer, only the MonarchE study has shown an improved invasive disease-free survival with abemaciclib taken for 2 years, whereas the Penelope-B did not meet the primary endpoint and the PALLAS study was terminated early for futility.Studies conducted in the neoadjuvant setting might help to explain the discordant results.